16:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
21:25 , Jun 5, 2018 |  BC Extra  |  Company News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
23:06 , Jan 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a chimeric, broadly neutralizing antibody (bNAb) against HIV gp41 that could help treat HIV infection. Thirty-five chimeric bNAbs were engineered by swapping the heavy and...
23:51 , Jan 6, 2017 |  BC Extra  |  Financial News

Frontier raises RMB300M in series C

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said it raised RMB300 million ($43.2 million) in a series C round led by Huaxin Century. Shenzhen Capital, Efung Capital and undisclosed other investors also participated. Frontier said it...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Albuvirtide: Interim Phase III data

Interim data from 96 evaluable HIV-infected patients who failed first-line antiretroviral therapy (ART) in the modified intent-to-treat (mITT) population of the open-label, Chinese Phase III TALENT trial showed that once-weekly 320 mg IV albuvirtide plus...